Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Articles (1)
- Ass'n for Molecular Pathology (1)
- BRCA 1 (1)
- BRCA 2 (1)
- Biologics (1)
-
- DNA (1)
- Diamond v. Chakrabarty (1)
- Erlotinib (1)
- Essays (1)
- FDA (1)
- Federal Circuit (1)
- Food and Drug Administration (1)
- Generic Drug (1)
- Genetic engineering (1)
- Hatch-Waxman (1)
- IVCDD (1)
- IVD (1)
- Mayo Collaborative Services (1)
- Myriad Genetics (1)
- Myriad I (1)
- Myriad II (1)
- Prometheus Laboratories (1)
Articles 1 - 2 of 2
Full-Text Articles in Law
The Illusion Of Interchangeability: The Benefits And Dangers Of Guidance-Plus Rulemaking In The Fda's Biosimilar Approval Process, Jonathan Stroud
The Illusion Of Interchangeability: The Benefits And Dangers Of Guidance-Plus Rulemaking In The Fda's Biosimilar Approval Process, Jonathan Stroud
Jonathan R. K. Stroud
On March 23, 2010, President Obama signed into law the ambitious Patient Protection and Affordable Care Act. While media attention focused largely on the sweeping changes the bill makes to the nation’s healthcare system, there was also a less-noticed rider to the bill, the Biologics Price Competition and Innovation Act of 2009 (Biosimilars Act). The Biosimilars Act grants the Food and Drug Administration (FDA) broad new authority to create an accelerated premarket approval pathway for generic competition to biologics in an attempt to drive biologic drug prices down and reduce the overall costs of health care. Traditionally, inventors of medical …
A Thousand Tiny Pieces: The Federal Circuit’S Fractured Myriad Ruling, Lessons To Be Learned, And The Way Forward, Jonathan R. K. Stroud
A Thousand Tiny Pieces: The Federal Circuit’S Fractured Myriad Ruling, Lessons To Be Learned, And The Way Forward, Jonathan R. K. Stroud
Jonathan R. K. Stroud
No abstract provided.